US Age-Related Macular Degeneration by Product Type (Dry AMD and Wet AMD) and by Drug (anti-Vascular Endothelial Growth Factor drugs (anti-VEGF), Lucentis (ranibizumab), Eylea (aflibercept), Avastin (bevacizumab) & Photodynamic therapy) By Route Of Administration (Intravenous & Intravitreal) Growth, Trends and Forecast, 2019-2028
- Published Date: 2022-12-26
- Report ID: 138123
- Pages: 200
-
Format:
Report Overview
The US Age-related macular degeneration (AMD) market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 1.8% during the forecast period
The age-related macular degeneration (AMD) is a disease in which the macula of the eyes small central region of the retina deteriorates. The macula is considered to be an essential component of the retina, as it regulates the visual perception of the eye. The ability of an individual to read, identify and recognize objects that require immaculate visual details determine macular health
TheUS is a majormarketforAMDin NorthAmerica andis projected to hold over 90% share in 2022
Market Drivers
Age related macular degeneration is a medical condition of the eye which diminishes the eyesight with age. Thus a rising geriatric population will contribute to growth of this market
With no actual cure for AMD, pharmaceutical companies are developing various drugs for the treatment. Thus a number of drugs are in the pipeline are undergoing development and trials for the treatment of AMD. Anti VEGF therapies are effective in treatment of wet AMD as they drain out the fluid leak and restore vision
1. US Age-Related Macular Degeneration Market Overview
A. Market Size
2. US Age-Related Macular Degeneration Market Growth Drivers
A. Rising geriatric population of Age-Related Macular Degeneration
B. Increase in pipeline drugs for Age-Related Macular Degeneration
3. US Age-Related Macular Degeneration Market Segmentation
A. By Product type
I. Dry AMD
II. Wet AMD
B. By Drugs
I. Anti-Vascular Endothelial Growth Factor drugs (Anti-VEGF)
II. Lucentis (ranibizumab)
III. Eylea (aflibercept)
IV. Avastin (bevacizumab)
V. Photodynamic therapy (PDT)
C. By Route Of Administration
I. Intravenous
II. Intravitreal
4. US Age-Related Macular Degeneration Major Market Share
A. Market Analysis, Insights and Forecast by Revenue
5. Competitive Landscape
A. Major Players
B. Products in Pipeline
6. Key Company Profiles
A. Roche Company overview, Product & Services, Strategies & Financials
B. Novartis Company overview, Product & Services, Strategies & Financials
C. Bayer Company overview, Product & Services, Strategies & Financials
7. Healthcare Policies and Regulatory Landscape.
A. Policy Changes and Reimbursement Scenario
8. Factors Driving Market Growth
A. Key Industry Developments
B. Mergers and Acquisitions
9. Market Opportunities and Future Trends
A. Market Opportunities
B. Future Trends
10. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
